Moosvi A R, Goldstein S, VanderBrug Medendorp S, Landis J R, Wolfe R A, Leighton R, Ritter G, Vasu C M, Acheson A
Henry Ford Heart and Vascular Institute, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 48202.
Am J Cardiol. 1990 May 15;65(18):1192-7. doi: 10.1016/0002-9149(90)90972-4.
The effect of empiric antiarrhythmic therapy with quinidine and procainamide on long-term mortality was examined in 209 patients with coronary artery disease resuscitated after out-of-hospital cardiac arrest. The antiarrhythmic agent used was determined by the patient's private physician without knowledge of the study ambulatory electrocardiogram. Of the 209 patients, procainamide was prescribed in 45 (22%), quinidine in 48 (23%) and no antiarrhythmic therapy in 116 (55%). Digoxin therapy was initiated in 101 patients. The 2-year total survival rate for the quinidine, procainamide and nontreated patients was 61, 57 and 71% (p less than 0.05), and for sudden death was 69, 69 and 89% (p less than 0.01), respectively. These observations suggest that empiric antiarrhythmic therapy in survivors of out-of-hospital cardiac arrest did not affect total mortality and was associated with an increased frequency of sudden death.
对209例院外心脏骤停复苏后的冠心病患者,研究了经验性应用奎尼丁和普鲁卡因胺进行抗心律失常治疗对长期死亡率的影响。抗心律失常药物的使用由患者的私人医生决定,其并不知晓该研究的动态心电图情况。209例患者中,45例(22%)使用了普鲁卡因胺,48例(23%)使用了奎尼丁,116例(55%)未接受抗心律失常治疗。101例患者开始使用地高辛治疗。奎尼丁组、普鲁卡因胺组和未治疗组患者的2年总生存率分别为61%、57%和71%(p<0.05),心源性猝死率分别为69%、69%和89%(p<0.01)。这些观察结果表明,院外心脏骤停幸存者的经验性抗心律失常治疗不影响总死亡率,且与心源性猝死发生率增加有关。